SCHEMBL29700410

SCHEMBL29700410

Nc1ncnc(-c2c[nH]c3ccccc23)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK5 Q00535 3/20 0.60
▸ CDK5R1 Q15078 3/20 0.60
▸ CLK1 P49759 2/20 0.60
▸ GSK3B P49841 1/20 0.60
▸ DYRK1A Q13627 1/20 0.60
▸ MAP3K14 Q99558 1/20 0.60
▸ MAPT P10636 4/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ PPARG P37231 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ NCOA2 Q15596 1/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.48
▸ PDGFRB P09619 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15903807 0.78 TDO2 (0.56) CDK5CDK5R1CLK1GSK3BDYRK1A
SCHEMBL29488162 0.75 GSK3B (1.00) CDK5CDK5R1CLK1GSK3BDYRK1A
SCHEMBL573402 0.75 GSK3B (1.00) CDK5CDK5R1CLK1GSK3BDYRK1A
SCHEMBL28228155 0.74 HSD17B10 (0.59) CDK5CDK5R1CLK1GSK3BDYRK1A
SCHEMBL20030496 0.74 DYRK1A (0.72) CDK5CDK5R1CLK1GSK3BDYRK1A
SCHEMBL28399449 0.74 MEN1 (0.65) CDK5CDK5R1CLK1GSK3BDYRK1A
SCHEMBL28228733 0.73 PI4KA (0.47) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL17179419 0.72 PDGFRB (0.62) CDK5CDK5R1CLK1GSK3BDYRK1A
SCHEMBL24839575 0.72 CLK1 (0.71) CDK5CDK5R1CLK1GSK3BDYRK1A
SCHEMBL16075920 0.72 CLK1 (0.71) CDK5CDK5R1CLK1GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258344-B2 Azaaromatic amide derivatives for the treatment of cancer SHENZHEN FORWARD PHARMACEUTICALS CO., LTD. (CN) 2025-03-25 — — US disclosed
US-20220177473-A1 AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER SHENZHEN FORWARD PHARMACEUTICALS CO., LTD. (CN) 2022-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177473-A1 AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER ERBB4, EGFR, ERBB2 CDK5 608/4885CDK5R1 1001/4885CLK1 4489/4885
US-12258344-B2 Azaaromatic amide derivatives for the treatment of cancer ERBB4, EGFR, ERBB2 CDK5 608/4885CDK5R1 1001/4885CLK1 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback